# Aram Salzman

> Aram Salzman is the CEO and co-founder of AngioWave Imaging, a Boston-area medtech company building AI that sharpens the blurry, fast-moving X-ray movies cardiologists rely on during heart catheterizations. He is a serial healthcare founder whose earlier company, NovoBiotic Pharmaceuticals, produced teixobactin, the first new class of antibiotic discovered in decades. He also co-founded and exited CRA Health and Boston Lighthouse Innovations.

- **Role:** CEO & Co-Founder at AngioWave Imaging
- **Organizations:** AngioWave Imaging, NovoBiotic Pharmaceuticals, CRA Health, Boston Lighthouse Innovations
- **Nationality:** American
- **Education:** B.A. in International Relations and American Literature, Brown University
- **Known for:** Co-founded and led NovoBiotic Pharmaceuticals, the company behind teixobactin - the first new class of antibiotic discovered in roughly three decades, published in Nature in January 2015, Founded and exited CRA Health, a cancer risk assessment software company, Co-founded and exited Boston Lighthouse Innovations

## Career timeline

- **2003** — Co-founded NovoBiotic Pharmaceuticals; served as President and CEO
- **2014** — Founded CRA Health, a cancer risk assessment software company, as founding CEO
- **2017** — Exited CRA Health
- **2024** — Co-founded AngioWave Imaging and became founding CEO
- **2026** — AngioWave secures Series B funding ($10M reported), backed by DRADS Capital

## Achievements

- Co-founded and led NovoBiotic Pharmaceuticals, the company behind teixobactin - the first new class of antibiotic discovered in roughly three decades, published in Nature in January 2015
- Founded and exited CRA Health, a cancer risk assessment software company
- Co-founded and exited Boston Lighthouse Innovations
- Built AngioWave Imaging to FDA 510(k) clearance for its AI angiography enhancement software with a team of four
- AngioWave holds nine granted USPTO patents with additional international filings

## Latest updates

- **2026-02** — AngioWave Imaging reported a Series B funding round (around $10M), backed by DRADS Capital.
- **2025-11** — AngioWave's AI-assisted analysis of septal collaterals for chronic total occlusion PCI featured in cardiology literature.

## Links

- Website: https://angiowave.ai
- LinkedIn: http://www.linkedin.com/in/aram-t-salzman-53412859

---

Profile page: https://yespress.io/aram-salzman
Published by YesPress — https://yespress.io
Last updated: 2026-06-14